Erythropoietin

Kendall, R.

doi:10.1046/j.1365-2257.2001.00351.x

Cited by 49 publications

(31 citation statements)

References 116 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…SGs were able to sustain serum hEPO levels well above the normal range (10-30 mU/ml; Kendall 2001) throughout the 16 weeks of the current experiment, and longer, as we have reported (Voutetakis et al 2004b). Erythropoietin targets erythroid progenitor cells in the bone marrow and increases red blood cell production and therefore Hct levels (Kendall 2001). Circulating hEPO proved to be not only therapeutically adequate but also functional in the present and in earlier studies: Hct levels in both AdhEPO-and AAVhEPO-treated groups generally followed serum hEPO levels (see Results).…”

Section: Discussionsupporting

confidence: 57%

Salivary glands as a potential gene transfer target for gene therapeutics of some monogenetic endocrine disorders

Voutetakis

Bossis²,

Kok³

et al. 2005

Journal of Endocrinology

View full text Add to dashboard Cite

Salivary glands (SGs) exhibit several important features which are also common to endocrine glands: selfcontainment due to a surrounding capsule, highly efficient protein production and the ability to secrete proteins into the bloodstream. We have hypothesized that SGs are potentially useful as gene transfer targets for the correction of inherited monogenetic endocrine disorders. In the present communication, we extend our studies and attempt to test our hypothesis by comparing the efficacy of two commonly used viral vectors and the resulting serum and salivary distribution of transgene encoded hormones.

show abstract

Section: Discussionsupporting

confidence: 57%

Salivary glands as a potential gene transfer target for gene therapeutics of some monogenetic endocrine disorders

Voutetakis

Bossis²,

Kok³

et al. 2005

Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…These drugs replace or supplement endogenous erythropoietin (EPO), the glycoprotein hormone responsible for maintaining an appropriate circulating red cell mass that delivers sufficient levels of oxygen to all tissues in the body (Kendall 2001).…”

Section: Introductionmentioning

confidence: 99%

Dose-related Differences in the Pharmacodynamic and Toxicologic Response to a Novel Hyperglycosylated Analog of Recombinant Human Erythropoietin in Sprague-Dawley Rats with Similarly High Hematocrit

et al. 2013

View full text Add to dashboard Cite

We recently reported results that erythropoiesis-stimulating agent (ESA)-related thrombotic toxicities in preclinical species were not solely dependent on a high hematocrit (HCT) but also associated with increased ESA dose level, dose frequency, and dosing duration. In this article, we conclude that sequelae of an increased magnitude of ESA-stimulated erythropoiesis potentially contributed to thrombosis in the highest ESA dose groups. The results were obtained from two investigative studies we conducted in Sprague-Dawley rats administered a low (no thrombotic toxicities) or high (with thrombotic toxicities) dose level of a hyperglycosylated analog of recombinant human erythropoietin (AMG 114), 3 times weekly for up to 9 days or for 1 month. Despite similarly increased HCT at both dose levels, animals in the high-dose group had an increased magnitude of erythropoiesis measured by spleen weights, splenic erythropoiesis, and circulating reticulocytes. Resulting prothrombotic risk factors identified predominantly or uniquely in the high-dose group were higher numbers of immature reticulocytes and nucleated red blood cells in circulation, severe functional iron deficiency, and increased intravascular destruction of iron-deficient reticulocyte/red blood cells. No thrombotic events were detected in rats dosed up to 9 days suggesting a sustained high HCT is a requisite cofactor for development of ESA-related thrombotic toxicities.

show abstract

“…It was observed in rats and other smaller mammals. All situations that decrease the oxygen amount usually transported to tissues, for instance anemia, longstanding cardiac insufficiency, bronchopulmonary diseases (emphysema, bronchitis, arteriovenous derivations) and staying at high altitudes increase erythrocyte production speed (15)(16)(17)18 . Hypoxia is a fundamental stimulus to erythropoiesis, but without a direct action on bone marrow.…”

Section: Discussionmentioning

confidence: 99%

Inhibition of rats extramedullary liver erytropoiesis by hyperbaric oxygen therapy

et al. 2007

View full text Add to dashboard Cite

Purpose: To research the hyperbaric oxygen therapy effects on rats' livers and spleens. Methods: 30 adult male Hotzman rats were used, being randomly distributed, by raffle, into 2 groups of 15 animals each: group 1 -control; group 2 -hyperbaric oxygen therapy. Group-2 animals underwent hyperbaric oxygen therapy for 120 minutes daily, 90 minutes of which were under pressure of 2.5 atmospheres. The first and last 15 minutes were used for gradual compression and decompression, respectively, for 20 days in a row. The livers and spleens of the animals from the two groups were taken out for histologic examination, on the day after the end of hyperbaric oxygen therapy in group 2 animals. Liver and spleen histologic changes of the animals from the two groups were compared by using Fisher exact test. P < 0.05 was regarded as a significant difference. Results: The only change in liver and spleen histology was the significant reduction in hepatic extramedullary erythropoiesis in the animals that underwent hyperbaric oxygen therapy (p < 0.05). Conclusion: Hyperbaric oxygen therapy reduces hepatic extramedullary erythropoiesis in rats and doesn't jeopardize the other liver and spleen structures. Key words: Hyperbaric oxygen. Erythropoiesis. Liver. RESUMOObjetivo: Pesquisar os efeitos da oxigenoterapia hiperbárica sobre o fígado e baço de ratos. Métodos: Foram utilizados 30 animais machos adultos da espécie Holtzman, distribuídos aleatoriamente e por sorteio em dois grupos de 15 animais cada, assim designados: grupo 1 -controle; grupo 2 -oxigenoterapia hiperbárica. Os animais do grupo 2 foram submetidos à oxigenoterapia hiperbárica por 120 minutos ao dia, sendo 90 minutos sob pressão de 2,5 atmosferas e 15 minutos iniciais e finais para a compressão e descompressão gradativa, respectivamente, em 20 dias consecutivos. Os fígados e baços dos animais dos dois grupos foram retirados para exame histológico, no dia seguinte após o término da oxigenoterapia hiperbárica nos animais do grupo 2. Compararam-se as alterações na histologia do fígado e baço entre os animais dos dois grupos empregando-se o teste exato de Fisher, considerando diferença significante o valor de p<0,05. Resultados: A única alteração na histologia dos fígados e baços foi a redução significativa da eritropoiese extramedular hepática nos animais submetidos a oxigenoterapia hiperbárica. (p < 0,05) Conclusão: A oxigenoterapia hiperbárica reduz a eritropoiese extramedular hepática em ratos e não compromete as demais estruturas do fígado e do baço. Descritores: Oxigenação hiperbárica. Eritropoese. Fígado. -ORIGINAL ARTICLE Costa-Val R et al 138

show abstract

Erythropoietin

Cited by 49 publications

References 116 publications

Salivary glands as a potential gene transfer target for gene therapeutics of some monogenetic endocrine disorders

Salivary glands as a potential gene transfer target for gene therapeutics of some monogenetic endocrine disorders

Dose-related Differences in the Pharmacodynamic and Toxicologic Response to a Novel Hyperglycosylated Analog of Recombinant Human Erythropoietin in Sprague-Dawley Rats with Similarly High Hematocrit

Inhibition of rats extramedullary liver erytropoiesis by hyperbaric oxygen therapy

Contact Info

Product

Resources

About